# PepGen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pepgen

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.pepgen.com/
- Total disclosed funding: $130M
- Latest round: Series B (Jul 30, 2021)
- Investors on record: 12

## About

PepGen Inc., based in the US, is a biotechnology company focused on developing innovative therapeutics for genetic neuromuscular and neurological diseases, utilizing advanced genetic therapies to improve patient outcomes.Founded in 2018 and headquartered in Cambridge, US, PepGen Inc. specializes in creating disease-modifying therapeutics targeting genetic conditions. The company has completed a total of 6 deals and successfully raised a total of USD 108.00 mn, with its latest funding round being an IPO. The current CEO is James McArthur.PepGen specializes in the development of innovative disease-modifying therapeutics targeting genetic neuromuscular and neurological diseases. Their core offerings include proprietary molecules aimed at addressing the underlying causes of these conditions, emphasizing therapies that can modify disease progression through targeted interventions. By utilizing advanced genetic therapy techniques, PepGen strives to deliver effective treatments for patients suffering from serious conditions, with a focus on neuromuscular disorders such as muscular dystrophies and spinal muscular atrophy. The company is engaged in clinical trials to validate the effectiveness of its therapeutics, anticipating future market launches in North America and Europe.PepGen's revenue model primarily relies on collaborations and partnerships within the pharmaceutical and biotechnology sectors, focusing on B2B transactions. They engage with healthcare providers, research organizations, and potentially other pharmaceutical firms to facilitate the distribution of their therapeutics. Revenue is expected to increase following successful clinical trial outcomes leading to product approvals, which would enable the commercialization of their proprietary therapies. Their flagship products, centered around the PGN-EDODM1 molecule, are projected to be competitively priced within the biotech industry, driving future revenue as they approach market launch.PepGen Inc. plans to expand its product line with new therapeutics targeting genetic neuromuscular diseases, with potential launch dates to be determined based on clinical trial results. The company is also exploring expansion into European markets, aiming for a rollout by 2025. Recent funding from the IPO will support these growth initiatives, allowing for increased investment in research and development. Additionally, CureDuchenne Ventures, Deerfield Management, Gray's Creek Capital Partners, and Tudor Investment Corporation have exited their stake in PepGen Inc. for an undisclosed amount, indicating a strategic shift in the company's investment landscape.

## Funding rounds

- Series B, Jul 30, 2021, $113M — Adage Capital Management, Viking Global Investors, Qatar Investment Authority, Tudor Investment Corporation, Laurion Capital Management, Deerfield Management, RA Capital Management, Gray's Creek Capital Partners, Oxford Sciences Enterprises, Samsara BioCapital, CureDuchenne Ventures
- Series A, Dec 9, 2020, $14M — RA Capital Management, University of Oxford, Oxford Sciences Enterprises, CureDuchenne Ventures
- Seed, Mar 26, 2018, $3.5M — Oxford Sciences Enterprises

## Investors

- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Seed, Series A, Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B
- University of Oxford — Series A
- CureDuchenne Ventures (https://capitalatlas.ai/funds/cureduchenne-ventures) — Series A, Series B
- Adage Capital Management — Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series B
- Tudor Investment Corporation — Series B
- Laurion Capital Management — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B
- Gray's Creek Capital Partners — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B